Medidata to Join Forces with Dassault Systèmes, Creating the First End-to-End Scientific and Business Platform for Life Sciences
Accelerating the digital transformation for Life Sciences has been our sole focus and commitment during the past 20 years. For pharmaceutical, biotech, and medical device companies, the promise of delivering precision medicine - with data-driven, insights-led decisions in real-time, and a full lifecycle platform to manage all data and operations - is paramount.
That’s why today, I’m so excited about our announcement that Medidata has entered into an agreement to be acquired by Dassault Systèmes, creating the world’s leading technology company for Life Sciences.
Fueled by a common vision to build sustainable innovation capable of improving people’s lives, Dassault Systèmes and Medidata are fully committed to enable our customers and partners to bring the right treatment, to the right patient, at the right time. Together, we are several steps closer to achieving our vision for personalized health and patient-centric experiences.
Our customers and partners now have an unprecedented ability to power their digital transformation with the only end-to-end platform for drug discovery, pre-clinical, clinical development, manufacturing, regulatory submission and commercialization. Our combined capabilities offer an unparalleled suite of platform-empowered capabilities including collaboration, modeling, simulation, lifecycle management, financial operations management, quality assurance, business intelligence and artificial intelligence.
This further enhances our customers ability to design and navigate the entire therapeutic lifecycle with one trusted partner.
I look forward to discussing this new area for life sciences with our industry leaders.